Verrica Pharmaceuticals (NASDAQ:VRCA) Given Hold Rating at Needham & Company LLC

Verrica Pharmaceuticals (NASDAQ:VRCA)‘s stock had its “hold” rating restated by stock analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.

Separately, HC Wainwright reissued a “neutral” rating on shares of Verrica Pharmaceuticals in a research note on Tuesday. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, Verrica Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $9.50.

Verrica Pharmaceuticals Stock Performance

NASDAQ VRCA opened at $0.44 on Wednesday. The business’s 50 day moving average price is $0.60 and its 200-day moving average price is $0.87. Verrica Pharmaceuticals has a fifty-two week low of $0.38 and a fifty-two week high of $11.41. The company has a market cap of $40.62 million, a P/E ratio of -0.24 and a beta of 1.68.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. The business had revenue of $0.34 million for the quarter, compared to analysts’ expectations of $1.30 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. As a group, equities analysts predict that Verrica Pharmaceuticals will post -1.46 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Caligan Partners LP purchased a new stake in Verrica Pharmaceuticals in the 4th quarter valued at about $5,201,000. Boothbay Fund Management LLC purchased a new stake in shares of Verrica Pharmaceuticals in the fourth quarter valued at approximately $1,811,000. Sovran Advisors LLC bought a new position in Verrica Pharmaceuticals in the fourth quarter worth approximately $267,000. Heights Capital Management Inc. purchased a new position in Verrica Pharmaceuticals during the 4th quarter worth $246,000. Finally, Rhumbline Advisers raised its position in Verrica Pharmaceuticals by 975.2% during the 4th quarter. Rhumbline Advisers now owns 266,093 shares of the company’s stock valued at $186,000 after purchasing an additional 241,344 shares in the last quarter. Hedge funds and other institutional investors own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.